Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How do second-line agents work?

E Choy1, G Kingsley

  • 1Rheumatology Unit, Division of Medicine, United Medical and Dental School of Guy's Hospital, London.

British Medical Bulletin
|April 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bringing light to the dark: an interview with Dr Cecilia Fan and her medical team.

Hong Kong medical journal = Xianggang yi xue za zhi·2025
Same author

SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.

ESMO open·2021
Same author

Dermatomyositis: a slow path towards targeted therapies or will conventional therapies prevail?

The British journal of dermatology·2018
Same author

Using fMRI to evaluate the effects of milnacipran on central pain processing in patients with fibromyalgia.

Scandinavian journal of pain·2018
Same author

The pathogenesis of dermatomyositis.

The British journal of dermatology·2017
Same author

EULAR revised recommendations for the management of fibromyalgia.

Annals of the rheumatic diseases·2016
Same journal

Augmentation in Achilles tendon repair: evidence versus enthusiasm.

British medical bulletin·2026
Same journal

Regional musculoskeletal pain in workers-is the traditional medical model increasing disability?

British medical bulletin·2026
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
See all related articles

The cause of rheumatoid arthritis is unknown, but disease-modifying anti-rheumatic drugs (DMARDs) treat patients. This review explores how established and novel DMARDs work, focusing on their anti-inflammatory and immunomodulatory effects.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • The exact cause of rheumatoid arthritis (RA) is not understood.
  • Disease-modifying anti-rheumatic drugs (DMARDs) are standard treatments for RA.
  • The mechanisms of action for DMARDs were discovered by chance and are not fully elucidated.

Purpose of the Study:

  • To review current hypotheses on the mechanisms of action of established DMARDs.
  • To discuss novel agents with potential as new DMARDs.
  • To provide insight into the anti-inflammatory and immunomodulatory properties of DMARDs.

Main Methods:

  • Literature review of established and novel disease-modifying anti-rheumatic drugs.
  • Analysis of current hypotheses regarding DMARD mechanisms.

Related Experiment Videos

  • Synthesis of information on anti-inflammatory and immunomodulatory effects.

    • Main Results:

    • Most established DMARDs exhibit anti-inflammatory properties.
    • Some DMARDs function as immunomodulators.
    • Several novel agents are under investigation as potential future DMARDs.

    Conclusions:

    • Understanding DMARD mechanisms is crucial for optimizing rheumatoid arthritis treatment.
    • Further research into novel agents may lead to more targeted and effective therapies.
    • DMARDs primarily act through anti-inflammatory and immunomodulatory pathways.